Declining Sales of Combustible Products: BAT Malaysia May Shift Focus to NTPs including Vuse

BAT by 2FIRSTS.ai
Feb.16.2024
Declining Sales of Combustible Products: BAT Malaysia May Shift Focus to NTPs including Vuse
BAT faces challenging profit prospects due to declining cigarette market, struggling to maintain sales amid increased competition and price gaps.

According to a report from Malaysian business media outlet Business Times, British American Tobacco (BAT) still faces challenges in terms of its profit prospects. The main reason is the lack of strong revenue streams in its new areas of business, coupled with a declining trend in the combustible cigarette market.

 

A study by Hong Leong Investment Bank (HLIB) shows that in the fiscal year 2023 (FY23), sales volume for BAT experienced a significant decrease, dropping by 12.9% compared to a smaller decline of 1 percentage point for the industry benchmark.

 

The significant decline can be attributed to two main factors: ongoing downgrading activities affecting BAT's premium and AP sales, which contribute to approximately 70% of the group's combustible cigarette sales, and a decrease in sales following a price increase in September 2023. In particular, price hikes for BAT's Dunhill and Peter Stuyvesant brands have created a price gap with competitors like Philip Morris International (PMI) and Japan Tobacco International (JTI), putting pressure on the group's fourth-quarter cigarette sales. Unless JTI and PMI also raise prices, it is expected that this will continue to impact BAT's sales performance.

 

Faced with a declining trend in the flammable cigarette market, BAT has launched a new brand called Luckies to diversify its brand offerings and protect its market share. Leveraging BAT's extensive sales network and the competitive price point of Luckies, this new brand has garnered positive attention since its launch.

 

According to a survey by BAT, consumer awareness increased from 16% in the first week after launch to 44% in the fifth week. According to tracking, Luckies' market share has increased from 0.1% in August 2023 to 1.4% in December 2023.

 

Meanwhile, currently, sales generated by the e-cigarette brand Vuse account for less than two percent of BAT's total sales, the group's goal is to have the new category (Vuse and THP) reach 30% of total sales in the next three to five years. "The main focus will be on expanding the Vuse product line, which involves increasing product supply and expanding the sales network.

 

British American Tobacco (BAT) plans to increase sales coverage by stocking Vuse products in more retail and e-cigarette stores. Currently, Vuse products are only available in 6,600 retail stores and 1,100 e-cigarette stores, significantly less than the 45,000 sales points for BAT combustible cigarettes, indicating room for growth.

 

However, in the early stages, the contribution of the new tobacco sector will still be a drop in the bucket.

 

Currently, HLIB has a "hold" rating on the stock, with a target price unchanged at 9.22 ringgit.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
Imperial Brands Plans Thousands of Job Cuts Across U.S. and Europe in Cost Restructuring
Imperial Brands Plans Thousands of Job Cuts Across U.S. and Europe in Cost Restructuring
According to Reuters, citing Bloomberg News, British tobacco company Imperial Brands PLC plans to cut thousands of jobs across the United States and Europe as part of a cost reduction and organizational restructuring effort. The announcement drew market attention to the company’s shares. The move comes as global tobacco companies continue adjusting their operations amid slower cigarette market growth, changing consumer preferences and the transition toward next-generation nicotine products.
Aug.11
From Nicotine Salts to Cocrystals: China’s Shenzhen Huabao institute explores a more stable form for sustained nicotine release
From Nicotine Salts to Cocrystals: China’s Shenzhen Huabao institute explores a more stable form for sustained nicotine release
China-based Shenzhen Huabao Collaborative Innovation Technology Research Institute Co., Ltd. has filed a patent application for a nicotine-ascorbic acid cocrystal, exploring a new solid-state form of nicotine. The patent proposes applications across e-liquids, heated tobacco sticks, oral tobacco, chewing tobacco and snuff. In nicotine pouch tests disclosed in the filing, cocrystal formulations showed less than a 6% decline in nicotine content after three months of accelerated storage and a release profile combining early-stage release with sustained delivery over 60 minutes. The filing reflects exploration of nicotine forms beyond conventional nicotine base and nicotine salts.
Aug.13
Product | VAPORESSO Launches PRIX MTL Pod, With NFC Version Linking Interchangeable Panels to On-Screen Animations
Product | VAPORESSO Launches PRIX MTL Pod, With NFC Version Linking Interchangeable Panels to On-Screen Animations
VAPORESSO introduced the PRIX MTL pod system in August 2026 in two versions, Filter and NFC. The Filter version allows users to switch between a conventional drip tip and a filter tip, while the NFC version links interchangeable panels to matching on-screen animations. PRIX features a 2,600mAh battery, a 5.5ml pod, a 0.87-inch TFT display and a maximum output of 40W, alongside Dual Mesh Impact Pods capable of operating at two resistance and power configurations. VAPORESSO's French website lists MSRP at $39.99 for the Filter version and $49.90 for the NFC version.
Market
Aug.24 by 2Firsts Perspectives